Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00124930

Enrollment

Registered

2005-07-29

Start date

2005-05-31

Completion date

2008-06-30

Last updated

2012-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea, Neoplasms

Keywords

olanzapine, haldol, cancer, nausea, second line treatment, refractory nausea

Brief summary

The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Detailed description

The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Interventions

DRUGOlanzapine

DRUGHaldol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \>18 years of age * Significant nausea/vomiting * Failed maxeran and domperidone * Underlying treatment of causes has failed * Adequate cognitive function * Communicates well

Exclusion criteria

* Partial/complete bowel obstruction * Currently taking Haldol or olanzapine * Has drug induced extrapyramidal symptoms * Parkinson's disease * Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus

Design outcomes

Primary

Measure	Time frame
Severity of nausea on days 3 and 5	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026